Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
To stimulate a broad discussion between academics, practicing physicians, corporate managers, and members of the regulatory community, we describe a proposal for a new regulatory pathway for human cell- and tissue-based products. The new components of the pathway are intended to accelerate patient access to a wide array of novel therapeutics, strengthen R&D infrastructure, and expand patient numbers and time lines for efficacy testing through a transparent and publicly accessible website for real-time reporting of outcome data and 5- to 10-year, long-term follow-up.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4006487 | PMC |
| http://dx.doi.org/10.5966/sctm.2013-0180 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Composite endpoints in health technology assessment: Part 1 - an illustration of best modeling practice.
J Comp Eff Res
September 2025
British Heart Foundation, University of Glasgow, Glasgow, UK.
Composite endpoints amalgamate multiple clinical outcomes into a single measure, offering efficiency gains in clinical trials through increased event rates and reduced sample sizes, thus accelerating clinical development and regulatory approval. However, employing composite endpoints introduces complexities into health technology assessments (HTAs), particularly in economic modeling, due to the varying clinical significance and cost implications of the components. In this paper, we explore best modeling practice for HTAs that are based on clinical trials that employ composite endpoints.
View Article and Find Full Text PDFBackground: Acupuncture is a widely recognized complementary therapy with proven therapeutic benefits; however, concerns regarding patient safety persist due to adverse events ranging from minor complications to severe outcomes like pneumothorax and nerve injury.
Objective: This study aims to identify common adverse events in acupuncture, propose innovative risk mitigation strategies, establish standardized best practices, enhance practitioner training, and examine global disparities in safety protocols.
Design: Comprehensive review of existing literature, clinical case studies, and international safety guidelines.
On the use and misuse of time-rescaling to assess the goodness-of-fit of self-exciting temporal point processes.
J Appl Stat
February 2025
RBS, International University of Rabat, Technopolis, Sala-Al-Jadida, Morocco.
The paper first highlights important drawbacks and biases related to the common use of time-rescaling to assess the goodness-of-fit (Gof) of self-exciting temporal point process (SETPP) models. Then it presents a new predictive time-rescaling approach leading to an asymptotically unbiased Gof framework for general SETPPs in the case of single observed trajectories. The predictive approach focuses on forecasting accuracy and addresses the bias problem resulting from the plugged-in estimated parameters.
View Article and Find Full Text PDFResolving a century-old enigma: potato 'Bolters' originate from instability of the StCDF1.3 allele.
Theor Appl Genet
September 2025
Plant Breeding, Wageningen University & Research, P.O. Box 386, 6700 AJ, Wageningen, The Netherlands.
Potato bolters are caused by excision of a transposon from the StCDF1.3 allele, resulting in a somatic mutant with late maturity. Somatic mutations during vegetative propagation can lead to novel genotypes, known as sports.
View Article and Find Full Text PDFArtificial Intelligence in allergy and immunology: recent developments, implementation challenges, and the road towards clinical impact.
J Allergy Clin Immunol
September 2025
University of Groningen, University Medical Center Groningen, Beatrix Children's Hospital, Department of Pediatric Pulmonology and Pediatric Allergology, Groningen, the Netherlands; University of Groningen, University Medical Center Groningen, Groningen Research Institute for Asthma and COPD (GRIAC)
Artificial intelligence (AI) is increasingly recognized for its capacity to transform medicine. While publications applying AI in allergy and immunology have increased, clinical implementation substantially lags behind other specialties. By mid-2024, over 1,000 FDA-approved AI-enabled medical devices existed, but none specifically addressed allergy and immunology.
View Article and Find Full Text PDF